重复经颅磁刺激联合艾司西酞普兰治疗女性首发抑郁症的早期疗效观察

目的:探讨重复经颅磁刺激(rTMS)联合艾司西酞普兰治疗女性首发抑郁症的早期疗效和安全性。方法:将50例抑郁症患者随机分为rTMS联合艾司西酞普兰组(研究组,n=25例)和单用艾司西酞普兰治疗组(对照组,n=25例)。采用汉密尔顿抑郁量表(HAMD)和抑郁自评量表(SDS)在治疗前和治疗第1、2、4、8周分别对两组患者评定疗效;治疗中用副反应量表(TESS)评定不良反应。结果:治疗前和第8周两组患者HAMD评分的差异无统计学意义(P均>0.05);治疗第1、2、4周末,研究组患者HAMD评分明显低于对照组,差异有统计学意义(P均<0.05),且治疗第4周末时,研究组显著优于对照组,差异有统计学意义(P<0.01)。两组间患者不良反应发生率差异无统计学意义(P>0.05)。结论:rTMS联合艾司西酞普兰治疗女性首发抑郁症早期疗效和安全性均优于单一用药。

Observation of early therapeutic effect of repetitive transcranial magnetic stimulation combined with escitalopram in treatment of women with first-episode depression

Objective：To investigate early therapeutic effect and safety of repetitive transcranial magnetic stimulation （rTMS）combined with escitalopram in treatment of female first-episode depression. Methods：A total of 50 patients with depression were ran-domly divided into rTMS combined with escitalopram treatment group （study group, n= 25 cases） and escitalopram treatment group（control group, n=25）. Hamilton Depression Scale （HAMD） and self rating Depression Scale （SDS） were used to assess the efficacybefore and 2, 4, and 8 weeks after the treatment, respectively; and treatment emergent symptom scale （TESS） was applied to assessadverse reactions. Results： There were no statistically significant differences in the HAMD scores for the two groups before and 8 weeksin two groups of HAMD score （P〉0. 05）. 1, 2, and 4 weeks after the treatment, the HAMD scores of study group were significantlylower than those of control group, and the differences were statistically significant （all P〈0. 05）; 4 weeks after the treatment, theHAMD scores of study group were significantly better than those of control group, and the differences were statistically significant （P〈0. 01）. The adverse reaction rate had no significant difference between the two groups （P〉0. 05）. Conclusions： rTMS combined withescitalopram in the treatment of female first-episode depression has the obvious early efficacy and its safety is better than that of thesingle drug.